Crystalline forms of a dipeptidyl peptidase-IV inhibitor
View Patent ↗Novel crystalline forms of (2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine are potent inhibitors of dipeptidyl peptidase-IV and are useful for the treatment of non-insulin dependent (Type 2) diabetes mellitus. The invention also relates to pharmaceutical compositions containing these novel forms, processes to prepare these forms and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes.
1. Crystalline (2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine of Compound I:
characterized by having at least four peaks in its powder X-ray diffraction pattern selected from the group consisting of 10.3±0.1 2θ, 12.7±0.1 2θ, 14.6±0.1 2θ, 16.1±0.1 2θ, 17.8±0.1 2θ, 19.2±0.1 2θ, 22.2±0.1 2θ, 24.1±0.1 2θ and 26.9±0.1 2θ.
2. The crystalline form of claim 1 characterized by the following four peaks in its powder X-ray diffraction pattern 17.8±0.1 2θ, 19.2±0.1 2θ, 22.2±0.1 2θ and 24.1+0.1 2θ.
3. Crystalline (2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine of Compound I:
characterized by having at least four peaks in its powder X-ray diffraction pattern selected from the group consisting of 7.5±0.1 2θ, 15.0±0.1 2θ, 16.2±0.1 2θ, 20.9±0.1 2θ, 22.0±0.1 2θ, 27.0±0.1 2θ, 27.6±0.1 2θ, 33.3+0.1 2θ.
4. The crystalline form of claim 3 characterized by the following four peaks in its powder X-ray diffraction pattern 20.9±0.1 2θ, 22.0±0.1 2θ, 27.0±0.1 2θ and 27.6±0.1 2θ.
5. Crystalline (2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine of Compound I:
characterized by having at least four peaks in its powder X-ray diffraction pattern selected from the group consisting of 14.5±0.1 2θ, 15.9±0.1 2θ, 17.3±0.1 2θ, 18.7±0.1 2θ, 19.5±0.1 2θ, 19.5±0.1 2θ, 21.2±0.1 2θ, 22.0±0.1 2θ and 23.2±0.1 2θ.
6. The crystalline form of claim 5 characterized by the following four peaks in its powder X-ray diffraction pattern 19.5±0.1 2θ, 21.2±0.1 2θ, 22.0±0.1 2θ and 23.2±0.1 2θ.
7. Crystalline (2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine of Compound I:
characterized by having at least four peaks in its powder X-ray diffraction pattern selected from the group consisting of 8.1±0.1 2θ, 10.6±0.1 2θ, 16.0±0.1 2θ, 16.9±0.1 2θ, 19.5±0.1 2θ, 21.3±0.1 2θ, 23.3±0.1 2θ and 25.4±0.1 2θ.
8. The crystalline form of claim 7 characterized by the following four peaks in its powder X-ray diffraction pattern 16.9±0.1 2θ, 19.5±0.1 2θ, 21.3±0.1 2θ and 23.3±0.1 2θ.
9. A method of treating Type 2 diabetes comprising administering to a mammal in need of such treatment a therapeutically effective amount of a crystalline form according to claim 1 .
10. A pharmaceutical composition comprising a drug substance that comprises crystalline (2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine of claim 1 and a pharmaceutically acceptable carrier.
11. A pharmaceutical composition of claim 10 , wherein at least 50% by weight of the crystalline form is present in the drug substance.
12. A pharmaceutical composition of claim 10 , wherein at least 5% by weight of the crystalline form is present in the drug substance.